Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies navigate potential margin pressures and competitive shifts.
Based on a technical and fundamental analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.
Over the past six months, Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest of the patient monitoring stocks fared in Q4.
Based on fundamental and technical analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD): a strong growth stock preparing for the next leg up?.
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom (NASDAQ:DXCM).
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends.
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 17.2% year on year to $597.5 million. Guidance for next quarter’s revenue was better than expected at $545.5 million at the midpoint, 0.7% above analysts’ estimates. Its non-GAAP profit of $1.15 per share was 12.6% above analysts’ consensus estimates.
